The European Commission has approved Janssen Pharmaceutical Cos.’s therapy for drug-resistant depression, Spravato (esketamine), allaying fears that written interventions from third parties may have delayed matters.
The nasal spray has been granted a label for use in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?